Previous 10 | Next 10 |
Socket Mobile (SCKT) +123% on Q3 results.Dogness (DOGZ) +60% after announcing partnership with Hangzhou Huayuan Pet Products and Shanghai Chongai Trading Co. Ltd.Zedge (ZDGE) +47% on Q4 results.Solid Biosciences (SLDB) +28% on announcing collaborat...
Kitov Pharma (KTOV) has announced new mechanism of action data of NT219, a dual inhibitor, small molecule targeting IRS1/2 and STAT3. Data were presented at the Epigenetics and Metabolism AACR Special Virtual Conference at Tel-Aviv University.The new data demonstrates IRS2-amplified colorecta...
Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion ...
Kitov Pharma (NASDAQ: KTOV ) announces that the first patient has been dosed in the Phase 1/2 clinical trial evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab, for the treatment of recurrent and/or metastatic solid tumors and hea...
TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the first patient has been dosed in th...
Kitov Pharma (NASDAQ: KTOV ) announces receipt of notification from the Chinese Patent Office to grant two separate patents for its lead oncology candidates CM24, a monoclonal antibody targeting CEACAM1, and NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, import...
Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries TEL AVIV, Israel, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class t...
Gevo (NASDAQ: GEVO ) -26% on launch of direct offering ; pared down overnight gains after Trafigura deal . More news on: Gevo, Inc., GAN Limited, Xcel Brands, Inc., Stocks on the move, , Read more ...
Kitov Pharma (NASDAQ: KTOV ) has changed the ratio of its ADSs to ordinary shares from 1 ADS representing 1 ordinary shares to a new ratio of 1 ADS representing 10 ordinary shares . More news on: Kitov Pharma Ltd, Read more ...
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced today that the Company will change the ratio of its ...
News, Short Squeeze, Breakout and More Instantly...
Kitov Pharma Ltd. Company Name:
KTOV Stock Symbol:
NASDAQ Market:
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple Biotech manageme...
Virtual Bell-Ringing Ceremony in Celebration of Company’s Recent Name Change to Purple Biotech REHOVOT, Israel, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class thera...
New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to o...